Literature DB >> 30291897

Protein-based nanoparticles in cancer vaccine development.

Medea Neek1, Tae Il Kim2, Szu-Wen Wang3.   

Abstract

Peptide and protein-based cancer vaccines usually fail to elicit efficient immune responses against tumors. However, delivery of these peptides and proteins as components within caged protein nanoparticles has shown promising improvements in vaccine efficacy. Advantages of protein nanoparticles over other vaccine platforms include their highly organized structures and symmetry, biodegradability, ability to be specifically functionalized at three different interfaces (inside and outside the protein cage, and between subunits in macromolecular assembly), and ideal size for vaccine delivery. In this review, we discuss different classes of virus-like particles and caged protein nanoparticles that have been used as vehicles to transport and increase the interaction of cancer vaccine components with the immune system. We review the effectiveness of these protein nanoparticles towards inducing and elevating specific immune responses, which are needed to overcome the low immunogenicity of the tumor microenvironment.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Caged protein nanoparticles; Cancer vaccines; Tumor antigens; Virus-like particles

Mesh:

Substances:

Year:  2018        PMID: 30291897      PMCID: PMC6289732          DOI: 10.1016/j.nano.2018.09.004

Source DB:  PubMed          Journal:  Nanomedicine        ISSN: 1549-9634            Impact factor:   5.307


  122 in total

1.  Long-term outcomes in patients with metastatic melanoma vaccinated with melanoma peptide-pulsed CD34(+) progenitor-derived dendritic cells.

Authors:  Joseph W Fay; A Karolina Palucka; Sophie Paczesny; Madhav Dhodapkar; Dennis A Johnston; Susan Burkeholder; Hideki Ueno; Jacques Banchereau
Journal:  Cancer Immunol Immunother       Date:  2005-12-06       Impact factor: 6.968

2.  Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine.

Authors:  J Banchereau; A K Palucka; M Dhodapkar; S Burkeholder; N Taquet; A Rolland; S Taquet; S Coquery; K M Wittkowski; N Bhardwaj; L Pineiro; R Steinman; J Fay
Journal:  Cancer Res       Date:  2001-09-01       Impact factor: 12.701

Review 3.  Biodegradable poly(lactic-co-glycolic acid) microparticles for injectable delivery of vaccine antigens.

Authors:  Wenlei Jiang; Rajesh K Gupta; Mangesh C Deshpande; Steven P Schwendeman
Journal:  Adv Drug Deliv Rev       Date:  2005-01-10       Impact factor: 15.470

4.  PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors.

Authors:  Michael A Curran; Welby Montalvo; Hideo Yagita; James P Allison
Journal:  Proc Natl Acad Sci U S A       Date:  2010-02-16       Impact factor: 11.205

Review 5.  Going viral with cancer immunotherapy.

Authors:  Brian D Lichty; Caroline J Breitbach; David F Stojdl; John C Bell
Journal:  Nat Rev Cancer       Date:  2014-07-03       Impact factor: 60.716

6.  Targeting vault nanoparticles to specific cell surface receptors.

Authors:  Valerie A Kickhoefer; Muri Han; Sujna Raval-Fernandes; Michael J Poderycki; Raymond J Moniz; Dana Vaccari; Mariena Silvestry; Phoebe L Stewart; Kathleen A Kelly; Leonard H Rome
Journal:  ACS Nano       Date:  2009-01-27       Impact factor: 15.881

7.  Anti-PD-1 inhibits Foxp3+ Treg cell conversion and unleashes intratumoural effector T cells thereby enhancing the efficacy of a cancer vaccine in a mouse model.

Authors:  Lydia Dyck; Mieszko M Wilk; Mathilde Raverdeau; Alicja Misiak; Louis Boon; Kingston H G Mills
Journal:  Cancer Immunol Immunother       Date:  2016-09-28       Impact factor: 6.968

8.  Bio-distribution, toxicity and pathology of cowpea mosaic virus nanoparticles in vivo.

Authors:  Pratik Singh; Duane Prasuhn; Robert M Yeh; Giuseppe Destito; Chris S Rae; Kent Osborn; M G Finn; Marianne Manchester
Journal:  J Control Release       Date:  2007-04-13       Impact factor: 9.776

9.  Significant Impact of Immunogen Design on the Diversity of Antibodies Generated by Carbohydrate-Based Anticancer Vaccine.

Authors:  Zhaojun Yin; Sudipa Chowdhury; Craig McKay; Claire Baniel; W Shea Wright; Philip Bentley; Katarzyna Kaczanowska; Jeffrey C Gildersleeve; M G Finn; Lbachir BenMohamed; Xuefei Huang
Journal:  ACS Chem Biol       Date:  2015-08-11       Impact factor: 5.100

Review 10.  Plant Viruses as Nanoparticle-Based Vaccines and Adjuvants.

Authors:  Marie-Ève Lebel; Karine Chartrand; Denis Leclerc; Alain Lamarre
Journal:  Vaccines (Basel)       Date:  2015-08-05
View more
  29 in total

1.  Pentaerythritol-based lipid A bolsters the antitumor efficacy of a polyanhydride particle-based cancer vaccine.

Authors:  Emad I Wafa; Sean M Geary; Kathleen A Ross; Jonathan T Goodman; Balaji Narasimhan; Aliasger K Salem
Journal:  Nanomedicine       Date:  2019-07-15       Impact factor: 5.307

Review 2.  Protein Nanoparticles: Uniting the Power of Proteins with Engineering Design Approaches.

Authors:  Nahal Habibi; Ava Mauser; Yeongun Ko; Joerg Lahann
Journal:  Adv Sci (Weinh)       Date:  2022-01-25       Impact factor: 16.806

3.  Tyrosine-Based Cross-Linking of Peptide Antigens to Generate Nanoclusters with Enhanced Immunogenicity: Demonstration Using the Conserved M2e Peptide of Influenza A.

Authors:  Logan R Wilks; Gaurav Joshi; Megan R Grisham; Harvinder Singh Gill
Journal:  ACS Infect Dis       Date:  2021-08-25       Impact factor: 5.578

4.  An Antigen-Delivery Protein Nanoparticle Combined with Anti-PD-1 Checkpoint Inhibitor Has Curative Efficacy in an Aggressive Melanoma Model.

Authors:  Medea Neek; Jo Anne Tucker; Nina Butkovich; Edward L Nelson; Szu-Wen Wang
Journal:  Adv Ther (Weinh)       Date:  2020-10-01

Review 5.  Advancements in protein nanoparticle vaccine platforms to combat infectious disease.

Authors:  Nina Butkovich; Enya Li; Aaron Ramirez; Amanda M Burkhardt; Szu-Wen Wang
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2020-11-08

6.  Single-Point Mutations in Qβ Virus-like Particles Change Binding to Cells.

Authors:  Marisa L Martino; Stephen N Crooke; Marianne Manchester; M G Finn
Journal:  Biomacromolecules       Date:  2021-07-12       Impact factor: 6.978

7.  A versatile photothermal vaccine based on acid-responsive glyco-nanoplatform for synergistic therapy of cancer.

Authors:  Yanan Gao; Qingyu Zhao; Min Xiao; Xuefei Huang; Xuanjun Wu
Journal:  Biomaterials       Date:  2021-04-08       Impact factor: 15.304

8.  Cowpea mosaic virus stimulates antitumor immunity through recognition by multiple MYD88-dependent toll-like receptors.

Authors:  Chenkai Mao; Veronique Beiss; Jennifer Fields; Nicole F Steinmetz; Steven Fiering
Journal:  Biomaterials       Date:  2021-05-25       Impact factor: 12.479

Review 9.  Chemical Conjugation Strategies for the Development of Protein-Based Subunit Nanovaccines.

Authors:  Lantian Lu; Viet Tram Duong; Ahmed O Shalash; Mariusz Skwarczynski; Istvan Toth
Journal:  Vaccines (Basel)       Date:  2021-05-28

10.  Self-assembled peptide and protein nanostructures for anti-cancer therapy: Targeted delivery, stimuli-responsive devices and immunotherapy.

Authors:  Masoud Delfi; Rossella Sartorius; Milad Ashrafizadeh; Esmaeel Sharifi; Yapei Zhang; Piergiuseppe De Berardinis; Ali Zarrabi; Rajender S Varma; Franklin R Tay; Bryan Ronain Smith; Pooyan Makvandi
Journal:  Nano Today       Date:  2021-03-11       Impact factor: 18.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.